FCCC LOGO Faculty Publications
Zacks S , Rogatko A , Babb J
Optimal Bayesian-feasible dose escalation for cancer phase I trials
Statistics & Probability Letters. 1998 Jun 15;38(3) :215-220
PMID: ISI:000074313800002   
Back to previous list
We present an adaptive dose escalation scheme for cancer phase I clinical trials which is based on a parametric quantal response model. The dose escalation is Bayesian-feasible, Bayesian-optimal and consistent. It is designed to approach the maximum tolerated dose as fast as possible subject to the constraint that the predicted probability of assigning doses higher than the maximum tolerated dose is equal to a specified value. (C) 1998 Elsevier Science B.V. All rights reserved.
Times Cited: 4 English Article ZV528 STAT PROBAB LETT